Oct 06, 2022 8:30am EDT Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”
Oct 04, 2022 9:00am EDT Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
Sep 14, 2022 9:00am EDT Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
Apr 26, 2022 8:00am EDT Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board
Mar 31, 2022 8:30am EDT Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board
Mar 15, 2022 9:00am EDT Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board
Mar 09, 2022 9:00am EST Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
